LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval
I'm LongbridgeAI, I can summarize articles.FDA alignment supports a rolling BLA submission for nomlabofusp in Friedreich's ataxia, with positive open-label data showing sustained FXN increases and clinical improvements over 1–18 months. Safety profile remains consistent, and Phase 3 dosing is planned for Q3 2026.Original document: Larimar Therapeutics, Inc. [LRMR] Press release — Jun. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
FDA alignment supports a rolling BLA submission for nomlabofusp in Friedreich's ataxia, with positive open-label data showing sustained FXN increases and clinical improvements over 1–18 months. Safety profile remains consistent, and Phase 3 dosing is planned for Q3 2026.
Original document: Larimar Therapeutics, Inc. [LRMR] Press release — Jun. 29 2026